The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://www.frontiersin.org/articles/10.3389/fimmu.2020.594911/full
I'm looking forward to the announcement this month that this product is launched in Germany. Not sure how they intend to market this, assuming it's an OTC product, but it could have amazing sales if it's as good as they think.
'The results of a successful allergy trial in a challenge chamber for ImmunoBon, our protein-based oral product for the general treatment of allergies which we acquired exclusive rights to in 2020, were published in the World Allergy Organisation Journal1 earlier this month. These show a significant improvement compared to baseline, while maintaining an excellent safety and tolerability profile. The product will be launched in Germany in January 2021.'
cautious drip drip buying, probably trying not to spook the offer.
Been tipped I wonder?
That was a good day:
> Good trading statement - revenues up, cash balance high;
> Confirmed launch of new product this month in Germany;
> Confirmed progress on clinical trials for two products this year;
> High trading volume in Shares and a close at the high of the day.
Exactly what I was thinking: it’s two ways from here. Either up or down...
Interesting, currently 20 @21p.
This rally might fizzle out back to mid-teens, as we've seen many times before, OR with some positive sentiment momentum it could test multi-year highs @28p.
seems to be some cautious fresh buying coming in.
Bullish trading update all things considered!
Now’s the time to hold tight then
Once again the MM is taking the Michael with the spread.
The trading statement was better than I had anticipated. Revenues and cash position were better, given how 2020 ended, than I thought they'd be.
2021 looks like an exciting year for the company !
@Andysmi - ditto
Well this was my opinion as well, though willing to hold and top up if people sell after the rns
I don't expect much from the trading statement, so wouldn't be surprised if there's a pullback after that. The real excitement for AGY lies in what it progresses this year through product development.
Getting more realistic!
one was delayed from an hour earlier
Hmmmm some interesting buys right at the bell! Tell you something??
Someone must’ve heard you - it’s narrowed substantially now (if lse data is correct)
Relatively active in the market so far today. If I remember correctly, this is one of those companies that seems to have very leaky RNS’s
And yes, the spread is awful. I can never be sure why this should be so - other than small markets for a penny AIM Share
Ridiculously large spread between buy & sell
Little tick up today!
Sales to y/e June 2020 were up by 7%, which indicates that sales in pharma may not have been as affected as other sectors during the pandemic. Yes, the full year only includes the March-June part of this crisis, but a significant part that covers the first lockdown.
If there was a material downturn, I believe there would already have been a Trading Statement to that effect.
Yes but I’m afraid it won’t be all good news as sales reported for previous months will be low, right?
Last year’s Trading Update/RNS was published on 16 Jan. I would expect this year’s to be by 20 Jan or thereabouts, and I would like to think that there will be sufficient positive progress reported to generate some interest from II’s & SP progress.
Good luck us!